drugset / Trial / NCT06134960
NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D/CLDN18.2-based CAR-T cells infusion in the treatment of advanced NKG2DL+/CLDN18.2+ solid tumors.
Timeline
- Start
- 2023-11-16
- Primary completion
- 2026-06-30
- Completion
- 2026-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KD-496 | Cell therapy | — | — |